Peter Attia· MD
and by the way in these trials where they measure low both serum and CSF des master all guess what there was a significantly increase incidence of Alzheimer's disease and mild cognitive impairment
Loading…
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
and by the way in these trials where they measure low both serum and CSF des master all guess what there was a significantly increase incidence of Alzheimer's disease and mild cognitive impairment
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
which would lead simply to the hypothesis that Serum desmo is a usable biomarker to say somebody at risk for Alzheimer's disease
epidemiologic study where they correlated low desol with serum desol people who had low serum desol had a much higher incidence of cognitive impairment and Alzheimer's disease
there are enough data suggesting that if desol levels are very low the risk of AD does indeed go up and the risk of dementia Beyond ad goes up